Dxcover Strengthens Leadership with World-Class Scientific & AI Experts

Glasgow, Scotland – Dxcover, a clinical-stage oncology diagnostics company, announced today a significant expansion of its Scientific Advisory Board (SAB) and Board of Directors. These strategic appointments bring a wealth of expertise across neurology, gynaecological and pancreatic oncology, clinical statistics, artificial intelligence, and commercial diagnostics, bolstering Dxcover’s capabilities as it progresses into its next phases of clinical translation and commercial growth.

The Scientific Advisory Board welcomes three globally recognized clinicians and researchers, enhancing Dxcover’s international clinical leadership:

• Professor Katy Peters MD PhD, Professor of Neurology and Neurosurgery at Duke University Medical Center, is a leading expert in neuro-oncology and clinical trial design. Her extensive knowledge of brain cancer care pathways and active involvement in translational research will be invaluable in bringing diagnostic innovations to the clinic.

• Professor Emma Crosbie MBChB(Hons) PhD MRCOG, Professor of Gynaecological Oncology at The University of Manchester and an NIHR Research Professor, is an internationally respected clinician-scientist. Her work focuses on the early detection and prevention of endometrial and ovarian cancers, with her clinical trial experience and biomarker research expertise set to support Dxcover’s development of early detection strategies.

• Professor William E. Fisher MD FACS, Vice Chair of Clinical Affairs and Director of the Elkins Pancreas Center at Baylor College of Medicine, is a leading authority in pancreatic surgery and oncology. His insights into high-mortality, hard-to-detect cancers will guide Dxcover’s efforts to address urgent clinical needs in pancreatic cancer diagnostics.

These new members join existing SAB experts, Professor Paul Brennan, a globally recognized brain cancer diagnostics expert, and Dr. Luke Pike, a radiation oncologist specializing in CNS malignancies from Memorial Sloan Kettering Cancer Center. Their continued contributions provide deep clinical and real-world insights, particularly regarding US healthcare systems and reimbursement models.

Further strengthening its leadership, Dxcover has appointed two new Non-Executive Directors to its Board, focusing on commercial and AI expertise to support its US expansion and revenue-stage growth:

• Marc Jones, Chief Executive Officer of Altoida, is a seasoned health technology executive with over 25 years of experience leading diagnostics, software, and AI-powered platforms. His track record includes successfully developing, gaining regulatory approval for, and commercially scaling multiple FDA-cleared and CE-marked products. His current work in developing AI-driven digital biomarkers for neurological diseases aligns directly with Dxcover’s mission to deliver accessible, AI-powered cancer detection tools.

• Stacy Chick is an experienced global commercial life sciences executive who has advised Dxcover since 2021. As former Chief Commercial Officer for Inivata (acquired by NeoGenomics) and Kiyatec, she has a proven ability to transition diagnostic innovations from research to commercial stages, build market presence, establish commercial operations, and scale revenues while optimizing reimbursement rates. Her strategic insights into global market access, reimbursement, and commercial scaling will be crucial for Dxcover’s go-to-market strategy and CLIA rollout.

Professor Matthew J. Baker, CEO and inventor of Dxcover, commented on the appointments: “We are honored to welcome such a distinguished group of scientific and commercial leaders to Dxcover. Their profound clinical insight and strategic expertise will be instrumental as we expand access to our platform, broaden its diagnostic menu to include additional cancer types, pursue regulatory milestones, and deliver our technology into the hands of physicians and their patients globally.”

Dxcover’s proprietary Multiomic Spectral Analysis platform (MOSA-Dx™) is designed to simplify early cancer diagnosis. This innovative approach detects the presence of disease from minute volumes of liquid samples, providing results within one day. Going beyond conventional liquid biopsy methods, the MOSA-Dx™ platform leverages the power of artificial intelligence to capture comprehensive biological data (the multiome), enabling early-stage detection of a range of solid tumors. Dxcover’s unique AI algorithms are built on extensive data, including over 9,000 patient samples and 250,000 spectra, ensuring robust diagnostic performance that can be tailored for high sensitivity or specificity. The test is intended to be a valuable tool for clinicians, facilitating rapid and appropriate patient management decisions. Dxcover’s proprietary technology is protected by global patents.

Headquartered in Glasgow, UK, with its US headquarters in Nashville, Tennessee, Dxcover’s vision is to become the world leader in liquid biopsy and artificial intelligence for the early detection of cancer, ultimately improving patient survival and quality of life. The company’s mission is to deploy its platform for the triage of high-mortality and hard-to-diagnose cancers in high-risk populations, thereby enhancing access to value-based cancer care.